WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317980
CAS#: 161967-81-3 (HCl)
Description: Grepafloxacin hydrochloride is an oral broad-spectrum fluoroquinolone antibacterial agent used to treat bacterial infections.
Hodoodo Cat#: H317980
Name: Grepafloxacin Hydrochloride
CAS#: 161967-81-3 (HCl)
Chemical Formula: C19H23ClFN3O3
Exact Mass: 0.00
Molecular Weight: 395.860
Elemental Analysis: C, 57.65; H, 5.86; Cl, 8.96; F, 4.80; N, 10.62; O, 12.13
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 119914-60-2 (free base) 161967-81-3 (HCl)
Synonym: Grepafloxacin Hydrochloride; OPC-17116; DSSTox_CID_26692; DSSTox_RID_81826; DSSTox_GSID_46692; grepafloxacin hydrochloride; OPC 17116; OPC-17116; Raxar;
IUPAC/Chemical Name: 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;hydrochloride
InChi Key: IEPMBYOIQGCVHO-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H22FN3O3.ClH/c1-10-8-22(6-5-21-10)15-7-14-16(11(2)17(15)20)18(24)13(19(25)26)9-23(14)12-3-4-12;/h7,9-10,12,21H,3-6,8H2,1-2H3,(H,25,26);1H
SMILES Code: CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F.Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
Soluble in DMSO, not in water | 0.0 | 100.00 |
The following data is based on the product molecular weight 395.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Watanabe M, Kobayashi M, Ogura J, Takahashi N, Yamaguchi H, Iseki K. Alteration of pharmacokinetics of grepafloxacin in type 2 diabetic rats. J Pharm Pharm Sci. 2014;17(1):25-33. PubMed PMID: 24735760.
2: Gontijo AV, Brillault J, Grégoire N, Lamarche I, Gobin P, Couet W, Marchand S.
Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1.
Ciprofloxacin, moxifloxacin, and grepafloxacin. Antimicrob Agents Chemother. 2014
Jul;58(7):3942-9. doi: 10.1128/AAC.02818-14. Epub 2014 May 5. PubMed PMID:
24798283; PubMed Central PMCID: PMC4068515.
3: Atkins HS, Spencer S, Brew SD, Jenner DC, Sefton AM, MacMillan AP, Brooks TJ, Simpson AJ. Evaluation of azithromycin, trovafloxacin and grepafloxacin as
prophylaxis against experimental murine Brucella melitensis infection. Int J
Antimicrob Agents. 2010 Jul;36(1):66-8. doi: 10.1016/j.ijantimicag.2009.10.003.
Epub 2009 Dec 21. PubMed PMID: 20022474.